Literature DB >> 3975439

Reirradiation of head and neck cancers. Presentation of 35 cases treated at the Gustave Roussy Institute.

D Langlois, F Eschwege, A Kramar, J M Richard.   

Abstract

Thirty-five patients with head and neck carcinoma who were treated with a second course of radiotherapy for relapse or second malignancy at the Gustave Roussy Institute between 1973 and 1981 were studied. Immediate tolerance for total doses greater than 80 Gy was good but 37% of patients suffered from delayed necrosis or bleeding. Thirty-seven per cent of lesions were locally controlled at 3 months and 97% of patients showed a subjective improvement to reirradiation. Local control was obtained in 53% of patients aged between 40 and 60 as compared to 19% in other age groups, and was obtained in 55% of patients who were irradiated a second time with a dose greater than 60 Gy as compared to 8% for doses less than 60 Gy. Complications following treatment are related to failure to achieve local control and area of second treatment fields greater than 70 cm2. Survival was worse for those patients having an interval less than 12 months between the two courses of irradiation and those in whom local control was not achieved.

Entities:  

Mesh:

Year:  1985        PMID: 3975439     DOI: 10.1016/s0167-8140(85)80006-2

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Reirradiation with IMRT for recurrent head and neck cancer: A single-institutional report on disease control, survival, and toxicity.

Authors:  Parveen Ahlawat; Sheh Rawat; Anjali Kakria; Bharti Devnani; Inderjit Kaur Wahi; David K Simson
Journal:  Rep Pract Oncol Radiother       Date:  2017-06-07

2.  A Retrospective Evaluation of Clinical Profile of Second Primary Head and Neck Cancer.

Authors:  Paramjeet Kaur; Nupur Bansal; J Vijaya Kumar; Anil Khurana; Ashok Chauhan
Journal:  J Clin Diagn Res       Date:  2016-10-01

3.  Outcome after re-irradiation of head and neck cancer patients.

Authors:  Nele Platteaux; Piet Dirix; Bianca Vanstraelen; Sandra Nuyts
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

4.  The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.

Authors:  Jean-Claude M Rwigema; Dwight E Heron; Robert L Ferris; Regiane S Andrade; Michael K Gibson; Yong Yang; Cihat Ozhasoglu; Athanassios E Argiris; Jennifer R Grandis; Steven A Burton
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

5.  CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers.

Authors:  Yu L Jiang; Na Meng; Jun J Wang; Ping Jiang; Hui Sh Yuan; Chen Liu; Ang Qu; Rui J Yang
Journal:  Radiat Oncol       Date:  2010-07-30       Impact factor: 3.481

Review 6.  Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy.

Authors:  Hideya Yamazaki; Naohiro Kodani; Mikio Ogita; Kengo Sato; Kengo Himei
Journal:  Radiat Oncol       Date:  2011-08-21       Impact factor: 3.481

7.  Re-irradiation of unresectable recurrent head and neck cancer: using Helical Tomotherapy as image-guided intensity-modulated radiotherapy.

Authors:  Songmi Jeong; Eun Jung Yoo; Ji Yoon Kim; Chi Wha Han; Ki Jun Kim; Chul Seung Kay
Journal:  Radiat Oncol J       Date:  2013-12-31

Review 8.  Carotid blowout syndrome: modern trends in management.

Authors:  Carlos Suárez; Verónica Fernández-Alvarez; Marc Hamoir; William M Mendenhall; Primoz Strojan; Miquel Quer; Carl E Silver; Juan P Rodrigo; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Manag Res       Date:  2018-11-13       Impact factor: 3.989

9.  An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy.

Authors:  Lihong Zhu; Yuliang Jiang; Junjie Wang; Weiqiang Ran; Huishu Yuan; Chen Liu; Ang Qu; Ruijie Yang
Journal:  World J Surg Oncol       Date:  2013-03-08       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.